Clinical trial
Phase Ib/IIa Study of Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT03974243 is registered in ClinicalTrials.gov with Chipscreen Biosciences, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase Ib/IIa Study of Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
- Lead sponsor
- Chipscreen Biosciences, Ltd.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 11, 2019
- Completion date
- December 31, 2021
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-hodgkin's lymphoma